Remote recovery of audio signals from videos of optical speckle patterns: a comparative study of signal recovery algorithms

Optical remote sensors are nowadays ubiquitously used, thanks to unprecedented advances in the last decade in photonics, machine learning and signal processing tools. In this work we study experimentally the remote recovery of audio signals from the silent videos of the movement of optical speckle patterns. This technique can be used even when in between the source and the receiver there is a medium that does not allow for the propagation of sound waves. We use a diode laser to generate a speckle pattern on the membrane of a loudspeaker and a low-cost CCD camera to record the video of the movement of the speckle pattern when the loudspeaker plays an audio signal. We perform a comparative analysis of six signal recovery algorithms. In spite of having different complexity and computational requirements, we find that the algorithms have (except for the simplest one) good performance in terms of the quality of the recovered signal. The best trade-off, in terms of computational costs and performance, is obtained with a new method that we propose, which recovers the signal from the weighted sum of the intensities of all the pixels, where the signs of the weights are determined by selecting a reference pixel and calculating the signs of the cross-correlations of the intensity of the reference pixel and the intensities of the other pixels

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

International audienceBACKGROUND Nusinersen is an antisense oligonucleotide drug that modulates pre-messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). METHODS We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2: 1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure (control group) on days 1, 29, 85, and 274. The primary end point was the least-squares mean change from baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 0 to 66, with higher scores indicating better motor function. Secondary end points included the percentage of children with a clinically meaningful increase from baseline in the HFMSE score (>= 3 points), an outcome that indicates improvement in at least two motor skills. RESULTS In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) and a least-squares mean decrease in the control group (by -1.9 points), with a significant between-group difference favoring nusinersen (least-squares mean difference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P< 0.001). This result prompted early termination of the trial. Results of the final analysis were consistent with results of the interim analysis. In the final analysis, 57% of the children in the nusinersen group as compared with 26% in the control group had an increase from baseline to month 15 in the HFMSE score of at least 3 points (P< 0.001), and the overall incidence of adverse events was similar in the nusinersen group and the control group (93% and 100%, respectively). CONCLUSIONS Among children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals; CHERISH ClinicalTrials. gov number, NCT02292537.